Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB)

Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses

Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors posit

Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors posit

Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the an

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advan

Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amg

The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly

US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock,

Constellation Brands (NYSE: STZ) rose in pre-market trading after reporting strong Q1 earnings and r

Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Adv

This biotechnology firm leverages machine learning to design novel protein therapeutics targeting un

SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today ann

Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweigh

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB)

Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(1.07) per share which missed the

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinic

Top Wall Street analysts changed outlook on top names. Check our analyst ratings page for upgrades,

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Generate Biomedicines (N

Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ:GENB) w

Morgan Stanley analyst Sean Laaman initiates coverage on Generate Biomedicines (NASDAQ:GENB) with

Piper Sandler analyst Edward Tenthoff initiates coverage on Generate Biomedicines (NASDAQ:GENB) w

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Generate Biomedicines (NASDAQ:GENB)

Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrade

Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ:GENB) wit

Guru Stock PicksKen Fisher has made the following transactions:Reduce in DEO by 23.8%Sold out in VSH

Ark Invest bought shares of MercadoLibre, Intellia Therapeutics, and Generate Biomedicines on Monday

One IPO and six SPACs came to market this past week, and one major issuer joined the pipeline as Feb

Flagship-backed Generate Biomedicines' shares fell 6.25% in its Nasdaq debut on Friday, giving the d

Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initia

SOMERVILLE, Mass., Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Genera

Drug developer Generate Biomedicines said on Monday it was aiming to raise as much as $425 million i

One small issuer and four blank check companies went public this past week as the IPO market continu